ResMed

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ResMed and other ETFs, options, and stocks.

About RMD

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. 

CEO
Michael J. Farrell
CEOMichael J. Farrell
Employees
10,600
Employees10,600
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1989
Founded1989
Employees
10,600
Employees10,600

RMD Key Statistics

Market cap
29.05B
Market cap29.05B
Price-Earnings ratio
19.31
Price-Earnings ratio19.31
Dividend yield
1.20%
Dividend yield1.20%
Average volume
1.75M
Average volume1.75M
High today
$201.89
High today$201.89
Low today
$198.21
Low today$198.21
Open price
$200.25
Open price$200.25
Volume
1.93M
Volume1.93M
52 Week high
$293.81
52 Week high$293.81
52 Week low
$180.27
52 Week low$180.27

Stock Snapshot

With a market cap of 29.05B, ResMed(RMD) trades at $200.29. The stock has a price-to-earnings ratio of 19.31 and currently yields dividends of 1.20%.

On 2026-06-29, ResMed(RMD) stock moved within a range of $198.21 to $201.89. With shares now at $200.29, the stock is trading +1.0% above its intraday low and -0.8% below the session's peak.

Trading volume for ResMed(RMD) stock has reached 1.93M, versus its average volume of 1.75M.

The stock's 52-week range extends from a low of $180.27 to a high of $293.81.

The stock's 52-week range extends from a low of $180.27 to a high of $293.81.

RMD News

Simply Wall St 1d
ResMed Could Be 23% Undervalued Following Its Sleep Apnea Growth Narrative

Advertisement ResMed stock snapshot after recent trading move ResMed (RMD) has drawn fresh attention after a recent uptick in trading, with the stock closing...

ResMed Could Be 23% Undervalued Following Its Sleep Apnea Growth Narrative
TipRanks 7d
ResMed price target lowered to $266 from $290 at KeyBanc

KeyBanc lowered the firm’s price target on ResMed (RMD) to $266 from $290 and keeps an Overweight rating on the shares. Last week’s attendance at the SLEEP APSS...

Analyst ratings

67%

of 30 ratings
Buy
66.7%
Hold
26.7%
Sell
6.7%

People also own

Based on the portfolios of people who own RMD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.